Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $35.71 Consensus Price Target from Analysts
Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) have earned an average rating of “Buy” from the nine brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy […]
Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) have earned an average rating of “Buy” from the nine brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy […]
